DHL

2-AMINO-ETHANETHIOL


View summary at Ligand Expo



Chemical Component Summary

Name2-AMINO-ETHANETHIOL
Synonyms2,3-DESHYDROLANTHIONINE
Identifiers2-aminoethanethiol
FormulaC2 H7 N S
Molecular Weight77.15
TypeL-PEPTIDE LINKING
Isomeric SMILESC(CS)N
InChIInChI=1S/C2H7NS/c3-1-2-4/h4H,1-3H2
InChIKeyUFULAYFCSOUIOV-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count11
Chiral Atom Count0
Bond Count10
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB00847 
NameCysteamine
Groups
  • approved
  • investigational
DescriptionCystinosis is a rare disease caused by mutations in the CTNS gene that encodes for cystinosin, a protein responsible for transporting cystine out of the cell lysosome. A defect in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and kidneys.[A218721] Several preparations of cysteamine exist for the treatment of cystinosis manifestations, some in capsule form, and others in ophthalmic solution form.[L15606,L15616] In particular, cystine deposits on the eye can cause significant discomfort throughout the day and require frequent treatment with eye drops, typically every waking hour.[L15611] On August 25th 2020, the first ophthalmic solution for cystinosis requiring only 4 daily treatments was granted FDA approval.[L15606] Cysteamine eye drops are a practical and effective option for those affected by ocular cystinosis. Marketed by Recordati Rare Diseases Inc., CYSTADROPS® reduce the burden of multiple frequent medications normally administered to those with cystinosis.[L15601]
Synonyms
  • Thioethanolamine
  • Cysteamine hydrochloride
  • Cysteamine
  • MEA
  • Mercaptaminum
Brand Names
  • Procysbi
  • Cystadrops
  • Cystaran
  • PROCYSBI Delayed-release
  • Cystagon
IndicationThe bitartrate salt of cysteamine is used for the oral treatment of nephropathic cystinosis and cystinuria in children 6 years old and above, and adults.[L15616] The hydrochloride salt, used in eye drop preparations, is indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.[L15601,L15606]
Categories
  • Alimentary Tract and Metabolism
  • Amines
  • Amino Acids and Derivatives
  • Cystine Depleting Agents
  • Cystine Disulfide Reduction
ATC-Code
  • A16AA04
  • S01XA21
CAS number60-23-1

Drug Targets

NameTarget SequencePharmacological ActionActions
Cystine-unknowncleavage
Neuropeptide Y receptor type 2MGPIGAEADENQTVEEMKVEQYGPQTTPRGELVPDPEPELIDSTKLIEVQ...unknownother/unknown
MyeloperoxidaseMGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAA...unknownsubstrate
Serum albuminMKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA...unknownbinder
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
CCDC/CSDXIJKIK01
PubChem118985556
PubChem6058
ChEBICHEBI:17141
ChEMBLCHEMBL602